Eli Lilly and Co (XSWX:LLY) Shares Outstanding (EOP): 894 Mil (As of Mar. 2026)


XSWX:LLY Eli Lilly and Co XSWX:LLY
100 GF Score
Price CHF915.00
GF Value CHF1,111.74
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Eli Lilly and Co Shares Outstanding (EOP)?

Eli Lilly and Co XSWX:LLY 100 Shares Outstanding (EOP) is 894 Mil as of Mar. 2026. GuruFocus rates XSWX:LLY with a GF Score™ of 100/100 and a GF Value™ of CHF1,111.74 (Modestly Undervalued). The stock has 5 warning signs investors should review.

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Eli Lilly and Co's shares outstanding for the quarter that ended in Mar. 2026 was 894 Mil.

Eli Lilly and Co's quarterly shares outstanding declined from Dec. 2025 (895 Mil) to Mar. 2026 (894 Mil). It means Eli Lilly and Co bought back shares from Dec. 2025 to Mar. 2026 .

Eli Lilly and Co's annual shares outstanding declined from Dec. 2024 (898 Mil) to Dec. 2025 (895 Mil). It means Eli Lilly and Co bought back shares from Dec. 2024 to Dec. 2025 .


Eli Lilly and Co  (XSWX:LLY) Shares Outstanding (EOP) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred net income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


Eli Lilly and Co Shares Outstanding (EOP) Related Terms


Eli Lilly and Co Shares Outstanding (EOP) Historical Data

* Premium members only.

The historical data trend for Eli Lilly and Co's Shares Outstanding (EOP) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Eli Lilly and Co Shares Outstanding (EOP) Chart

Eli Lilly and Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Shares Outstanding (EOP)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 953.65 950.18 899.38 897.54 894.80

Eli Lilly and Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Shares Outstanding (EOP) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 897.73 896.83 895.84 894.80 893.50

XSWX:LLY vs JNJ, ABBV, MRK: Shares Outstanding (EOP) Comparison

For the Drug Manufacturers - General subindustry, Eli Lilly and Co's Shares Outstanding (EOP), along with its competitors' market caps and Shares Outstanding (EOP) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Eli Lilly and Co Shares Outstanding (EOP) vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Eli Lilly and Co's Shares Outstanding (EOP) distribution charts can be found below:

* The bar in red indicates where Eli Lilly and Co's Shares Outstanding (EOP) falls into.


XSWX:LLY
100GF Score
Eli Lilly and Co XSWX:LLY
Shares Outstanding (EOP) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Eli Lilly and Co Shares Outstanding (EOP) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that end of period. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.

What does a Shares Outstanding (EOP) of 894 Mil mean?
Eli Lilly and Co (XSWX:LLY) has a Shares Outstanding (EOP) of 894 Mil as of Mar. 2026. The total shares a company has outstanding, at period-end. View historical data on Eli Lilly and Co and its competitors.
Is Eli Lilly and Co's Shares Outstanding (EOP) too high?
Eli Lilly and Co's current Shares Outstanding (EOP) is 894 Mil. Overall, Eli Lilly and Co has a GF Score™ of 100/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Eli Lilly and Co's Shares Outstanding (EOP) compare to JNJ and ABBV?
Eli Lilly and Co's Shares Outstanding (EOP) of 894 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shares Outstanding (EOP) for a Drug Manufacturers company?
A good Shares Outstanding (EOP) depends on the Drug Manufacturers industry context. However, Shares Outstanding (EOP) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shares Outstanding (EOP) mean?
A high Shares Outstanding (EOP) can signal that a stock is expensive relative to its fundamentals. The total shares a company has outstanding, at period-end. View historical data on Eli Lilly and Co and its competitors. Eli Lilly and Co's current Shares Outstanding (EOP) is 894 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eli Lilly and Co stock overvalued right now?
Based on GuruFocus' analysis, Eli Lilly and Co (XSWX:LLY) is currently considered Modestly Undervalued. The stock's GF Value™ is CHF1,111.74, compared to a current price of CHF915.00 — trading 17.7% below its estimated fair value. The current Shares Outstanding (EOP) is 894 Mil. Eli Lilly and Co's overall GF Score™ is 100/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shares Outstanding (EOP) calculated?
Shares Outstanding (EOP) is calculated from a company's financial statements. For Eli Lilly and Co (XSWX:LLY), the current Shares Outstanding (EOP) is 894 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Eli Lilly and Co (XSWX:LLY) Overvalued in 2026?

Based on GuruFocus' analysis, Eli Lilly and Co stock appears to be undervalued. The current stock price of CHF915.00 is trading 17.7% below its estimated GF Value™ of CHF1,111.74. GuruFocus considers Eli Lilly and Co to be Modestly Undervalued.

Key valuation signals for XSWX:LLY:

  • Shares Outstanding (EOP): 894 Mil
  • GF Value™: CHF1,111.74 vs. price of CHF915.00 (17.7% below fair value)
  • GF Score™: 100/100 with 5 warning signs

No single metric tells the full story. See the XSWX:LLY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Eli Lilly and Co Business Description

Address Lilly Corporate Center, Indianapolis, IN, USA, 46285
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
100GF Score

Get the complete analysis for XSWX:LLY

Shares Outstanding (EOP) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF915.00
Price
CHF1,111.74
GF Value